Literature DB >> 24199663

Major histocompatibility complex I in brain development and schizophrenia.

A Kimberley McAllister1.   

Abstract

Although the etiology of schizophrenia (SZ) remains unknown, it is increasingly clear that immune dysregulation plays a central role. Genome-wide association studies reproducibly indicate an association of SZ with immune genes within the major histocompatibility complex (MHC). Moreover, environmental factors that increase risk for SZ, such as maternal infection, alter peripheral immune responses as well as the expression of immune molecules in the brain. MHC class I (MHCI) molecules might mediate both genetic and environmental contributions to SZ through direct effects on brain development in addition to mediating immunity. MHCI molecules are expressed on neurons in the central nervous system throughout development and into adulthood, where they regulate many aspects of brain development, including neurite outgrowth, synapse formation and function, long-term and homeostatic plasticity, and activity-dependent synaptic refinement. This review summarizes our current understanding of MHCI expression and function in the developing brain as well as its involvement in maternal immune activation, from the perspective of how these roles for MHCI molecules might contribute to the pathogenesis of SZ.
© 2013 Society of Biological Psychiatry Published by Society of Biological Psychiatry All rights reserved.

Entities:  

Keywords:  Cytokines; infection; maternal immune activation; neuroimmunology; synapse formation; synaptic plasticity

Mesh:

Year:  2013        PMID: 24199663      PMCID: PMC4354937          DOI: 10.1016/j.biopsych.2013.10.003

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  100 in total

Review 1.  LTP and LTD: an embarrassment of riches.

Authors:  Robert C Malenka; Mark F Bear
Journal:  Neuron       Date:  2004-09-30       Impact factor: 17.173

Review 2.  NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia.

Authors:  Guillermo Gonzalez-Burgos; David A Lewis
Journal:  Schizophr Bull       Date:  2012-02-21       Impact factor: 9.306

3.  Viral persistence in neurons explained by lack of major histocompatibility class I expression.

Authors:  E Joly; L Mucke; M B Oldstone
Journal:  Science       Date:  1991-09-13       Impact factor: 47.728

Review 4.  Maternal infection and schizophrenia: implications for prevention.

Authors:  Alan S Brown; Paul H Patterson
Journal:  Schizophr Bull       Date:  2010-12-06       Impact factor: 9.306

5.  Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients.

Authors:  G Degreef; M Ashtari; B Bogerts; R M Bilder; D N Jody; J M Alvir; J A Lieberman
Journal:  Arch Gen Psychiatry       Date:  1992-07

6.  Enhanced neuronal expression of major histocompatibility complex class I leads to aberrations in neurodevelopment and neurorepair.

Authors:  Zhongqi-Phyllis Wu; Lorraine Washburn; Tina V Bilousova; Maia Boudzinskaia; Nathalie Escande-Beillard; Jyes Querubin; Hoa Dang; Cui-Wei Xie; Jide Tian; Daniel L Kaufman
Journal:  J Neuroimmunol       Date:  2010-10-14       Impact factor: 3.478

7.  Neurons preferentially respond to self-MHC class I allele products regardless of peptide presented.

Authors:  Nathalie Escande-Beillard; Lorraine Washburn; Dan Zekzer; Zhongqi-Phyllis Wu; Shoshy Eitan; Sonja Ivkovic; Yuxin Lu; Hoa Dang; Blake Middleton; Tina V Bilousova; Yoshitaka Yoshimura; Christopher J Evans; Sebastian Joyce; Jide Tian; Daniel L Kaufman
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

8.  Common variants on chromosome 6p22.1 are associated with schizophrenia.

Authors:  Jianxin Shi; Douglas F Levinson; Jubao Duan; Alan R Sanders; Yonglan Zheng; Itsik Pe'er; Frank Dudbridge; Peter A Holmans; Alice S Whittemore; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Raymond R Crowe; Jorge R Oksenberg; Daniel B Mirel; Kenneth S Kendler; Robert Freedman; Pablo V Gejman
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

9.  Neuronal MHC class I molecules are involved in excitatory synaptic transmission at the hippocampal mossy fiber synapses of marmoset monkeys.

Authors:  Adema Ribic; Mingyue Zhang; Christina Schlumbohm; Kerstin Mätz-Rensing; Barbara Uchanska-Ziegler; Gabriele Flügge; Weiqi Zhang; Lutz Walter; Eberhard Fuchs
Journal:  Cell Mol Neurobiol       Date:  2010-03-16       Impact factor: 5.046

10.  NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia.

Authors:  Melissa A Snyder; Wen-Jun Gao
Journal:  Front Cell Neurosci       Date:  2013-03-27       Impact factor: 5.505

View more
  50 in total

1.  Kynurenine and Tryptophan Levels in Patients With Schizophrenia and Elevated Antigliadin Immunoglobulin G Antibodies.

Authors:  Olaoluwa Okusaga; Dietmar Fuchs; Gloria Reeves; Ina Giegling; Annette M Hartmann; Bettina Konte; Marion Friedl; Maureen Groer; Thomas B Cook; Kelly A Stearns-Yoder; Janardan P Pandey; Deanna L Kelly; Andrew J Hoisington; Christopher A Lowry; William W Eaton; Lisa A Brenner; Dan Rujescu; Teodor T Postolache
Journal:  Psychosom Med       Date:  2016-10       Impact factor: 4.312

Review 2.  Deciphering microbiome and neuroactive immune gene interactions in schizophrenia.

Authors:  Emily G Severance; Robert H Yolken
Journal:  Neurobiol Dis       Date:  2018-11-22       Impact factor: 5.996

3.  Increased circulating regulatory T cells in medicated people with schizophrenia.

Authors:  Deanna L Kelly; Xin Li; Catherine Kilday; Stephanie Feldman; Sarah Clark; Fang Liu; Robert W Buchanan; Leonardo H Tonelli
Journal:  Psychiatry Res       Date:  2018-09-05       Impact factor: 3.222

Review 4.  Neurodevelopment, GABA system dysfunction, and schizophrenia.

Authors:  Martin J Schmidt; Karoly Mirnics
Journal:  Neuropsychopharmacology       Date:  2014-04-24       Impact factor: 7.853

5.  Maternal immune activation in rats blunts brain cytokine and kynurenine pathway responses to a second immune challenge in early adulthood.

Authors:  Sarah M Clark; Francesca M Notarangelo; Xin Li; Shuo Chen; Robert Schwarcz; Leonardo H Tonelli
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-09-27       Impact factor: 5.067

Review 6.  Kraepelin revisited: schizophrenia from degeneration to failed regeneration.

Authors:  P Falkai; M J Rossner; T G Schulze; A Hasan; M M Brzózka; B Malchow; W G Honer; A Schmitt
Journal:  Mol Psychiatry       Date:  2015-03-31       Impact factor: 15.992

Review 7.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

8.  Long-term altered immune responses following fetal priming in a non-human primate model of maternal immune activation.

Authors:  Destanie R Rose; Milo Careaga; Judy Van de Water; Kim McAllister; Melissa D Bauman; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2016-11-19       Impact factor: 7.217

Review 9.  Systems psychopharmacology: A network approach to developing novel therapies.

Authors:  Peter J Gebicke-Haerter
Journal:  World J Psychiatry       Date:  2016-03-22

10.  CNS-wide Sexually Dimorphic Induction of the Major Histocompatibility Complex 1 Pathway With Aging.

Authors:  Colleen A Mangold; Dustin R Masser; David R Stanford; Georgina V Bixler; Aditya Pisupati; Cory B Giles; Jonathan D Wren; Matthew M Ford; William E Sonntag; Willard M Freeman
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-01-18       Impact factor: 6.053

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.